News

Find News

Filter articles

Applied Filters

Showing 851 to 860 of 910 results

Teva to lose grip on Copaxone next year

US20-11-2013Legal developments

The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.

Senate IP counsel set for Covington switch

US13-11-2013

Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.

Forest and Actavis settle over blood pressure drug

US08-11-2013

US pharmaceutical company Forest Laboratories and drug company Actavis have settled a legal dispute over a patent protecting blood pressure drug Bystoli (nebivolol).

SPC questions referred to CJEU in Actavis v Boehringer

EU, UK07-11-2013

The UK Patents Court has referred four questions to the CJEU seeking clarification on how the SPC Regulation should be interpreted in relation to drug products made of a combination of active ingredients.

Indian Patent Office rejects bid for cancer drug compulsory licence

India31-10-2013

The Indian Patent Office has rejected an application for a compulsory licence that was filed by domestic drug maker BDR Pharmaceuticals.

Arnold clears conflict of interest in SPC trial

UK28-10-2013

Mr Justice Arnold has refused to recuse himself from a patent trial after he was accused of being conflicted by an expert witness.

Radcliffe leaves Mayer Brown for Charles Russell

UK16-10-2013

Patent litigator Jonathan Radcliffe has left Mayer Brown to become partner at Charles Russell LLP.

Bayer takes another swipe at Nexavar compulsory licence

India15-10-2013Legal developments

Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Teva wins Netherlands Copaxone case

Netherlands04-10-2013

Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

FTC restricts Mylan’s acquisition of Agila amid antitrust fears

US02-10-2013

Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the FTC applied conditions to the deal.

Showing 851 to 860 of 910 results

LSIPR